Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101


Phase II trial of single agent cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rash.

Schilder RJ, Pathak HB, Lokshin AE, Holloway RW, Alvarez RD, Aghajanian C, Min H, Devarajan K, Ross E, Drescher CW, Godwin AK.

Gynecol Oncol. 2009 Apr;113(1):21-7. doi: 10.1016/j.ygyno.2008.12.003. Epub 2009 Jan 21.


Phase II trial of cetuximab and carboplatin in relapsed platinum-sensitive ovarian cancer and evaluation of epidermal growth factor receptor expression: a Gynecologic Oncology Group study.

Secord AA, Blessing JA, Armstrong DK, Rodgers WH, Miner Z, Barnes MN, Lewandowski G, Mannel RS; Gynecologic Oncology Group.

Gynecol Oncol. 2008 Mar;108(3):493-9. doi: 10.1016/j.ygyno.2007.11.029. Epub 2008 Jan 14.


A phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced-stage ovarian, primary peritoneal, or fallopian tube cancer.

Konner J, Schilder RJ, DeRosa FA, Gerst SR, Tew WP, Sabbatini PJ, Hensley ML, Spriggs DR, Aghajanian CA.

Gynecol Oncol. 2008 Aug;110(2):140-5. doi: 10.1016/j.ygyno.2008.04.018. Epub 2008 Jun 13.


Escalating weekly doses of cetuximab and correlation with skin toxicity: a phase I study.

Ho C, Sangha R, Beckett L, Tanaka M, Lau DH, Eisen DB, Burich RA, Luciw P, Khan I, Mack PC, Gandara DR, Davies AM.

Invest New Drugs. 2011 Aug;29(4):680-7. doi: 10.1007/s10637-010-9396-4. Epub 2010 Feb 12.


A Phase II clinical trial of pegylated liposomal doxorubicin and carboplatin in Japanese patients with platinum-sensitive recurrent ovarian, fallopian tube or primary peritoneal cancer.

Nakanishi T, Aoki D, Watanabe Y, Ando Y, Tomotsugu N, Sato Y, Saito T.

Jpn J Clin Oncol. 2015 May;45(5):422-6. doi: 10.1093/jjco/hyv016. Epub 2015 Feb 10.


A phase I trial of intravenous melphalan, paclitaxel, and cisplatin plus granulocyte-colony stimulating factor in patients with suboptimal advanced epithelial ovarian carcinoma or peritoneal carcinoma.

Gershenson DM, Morris M, Burke TW, Levenback C, Wolf J, Lee JJ, Thall PF, Atkinson EN, Silva EG, Wharton JT.

Cancer. 1999 Dec 1;86(11):2291-300.


Phase II study of weekly topotecan in patients with recurrent or persistent epithelial ovarian cancer.

Levy T, Inbar M, Menczer J, Grisaru D, Glezerman M, Safra T.

Gynecol Oncol. 2004 Dec;95(3):686-90.


Topotecan weekly bolus chemotherapy for relapsed platinum-sensitive ovarian and peritoneal cancers.

Morris R, Alvarez RD, Andrews S, Malone J, Bryant C, Heilbrun LK, Smith D, Schimp V, Munkarah A.

Gynecol Oncol. 2008 Jun;109(3):346-52. doi: 10.1016/j.ygyno.2008.02.028. Epub 2008 Apr 14.


A randomized phase II study of cetuximab every 2 weeks at either 500 or 750 mg/m2 for patients with recurrent or metastatic head and neck squamous cell cancer.

Fury MG, Sherman E, Lisa D, Agarwal N, Algazy K, Brockstein B, Langer C, Lim D, Mehra R, Rajan SK, Korte S, Lipson B, Yunus F, Tanvetyanon T, Smith-Marrone S, Ng K, Xiao H, Haque S, Pfister DG.

J Natl Compr Canc Netw. 2012 Nov 1;10(11):1391-8.


The use of weekly topotecan in the treatment of heavily pretreated recurrent epithelial ovarian and primary peritoneal cancer: the Kaohsiung Chang Gung experience.

Hu CF, Ou YC, Fu HC, Chang Chien CC, Tsai CC, Wu CH, Lin H.

Taiwan J Obstet Gynecol. 2015 Feb;54(1):43-7. doi: 10.1016/j.tjog.2014.11.005.


Phase II evaluation of imatinib mesylate in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group Study.

Schilder RJ, Sill MW, Lee RB, Shaw TJ, Senterman MK, Klein-Szanto AJ, Miner Z, Vanderhyden BC.

J Clin Oncol. 2008 Jul 10;26(20):3418-25. doi: 10.1200/JCO.2007.14.3420.


Randomised phase II study of docetaxel plus vandetanib versus docetaxel followed by vandetanib in patients with persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: SWOG S0904.

Coleman RL, Moon J, Sood AK, Hu W, Delmore JE, Bonebrake AJ, Anderson GL, Chambers SK, Markman M.

Eur J Cancer. 2014 Jun;50(9):1638-48. doi: 10.1016/j.ejca.2014.03.005. Epub 2014 Apr 4.


Phase II trial of cetuximab in patients with previously treated non-small-cell lung cancer.

Hanna N, Lilenbaum R, Ansari R, Lynch T, Govindan R, Jänne PA, Bonomi P.

J Clin Oncol. 2006 Nov 20;24(33):5253-8.


Predictive and prognostic angiogenic markers in a gynecologic oncology group phase II trial of bevacizumab in recurrent and persistent ovarian or peritoneal cancer.

Han ES, Burger RA, Darcy KM, Sill MW, Randall LM, Chase D, Parmakhtiar B, Monk BJ, Greer BE, Connelly P, Degeest K, Fruehauf JP.

Gynecol Oncol. 2010 Dec;119(3):484-90. doi: 10.1016/j.ygyno.2010.08.016. Epub 2010 Sep 25.


Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer.

Han SW, Oh DY, Im SA, Park SR, Lee KW, Song HS, Lee NS, Lee KH, Choi IS, Lee MH, Kim MA, Kim WH, Bang YJ, Kim TY.

Br J Cancer. 2009 Jan 27;100(2):298-304. doi: 10.1038/sj.bjc.6604861. Epub 2009 Jan 6.


A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study.

Modesitt SC, Sill M, Hoffman JS, Bender DP; Gynecologic Oncology Group.

Gynecol Oncol. 2008 May;109(2):182-6. doi: 10.1016/j.ygyno.2008.01.009. Epub 2008 Mar 4.


Docetaxel or pemetrexed with or without cetuximab in recurrent or progressive non-small-cell lung cancer after platinum-based therapy: a phase 3, open-label, randomised trial.

Kim ES, Neubauer M, Cohn A, Schwartzberg L, Garbo L, Caton J, Robert F, Reynolds C, Katz T, Chittoor S, Simms L, Saxman S.

Lancet Oncol. 2013 Dec;14(13):1326-36. doi: 10.1016/S1470-2045(13)70473-X. Epub 2013 Nov 12. Erratum in: Lancet Oncol. 2014 Jan;15(1):e4.


Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck.

Baselga J, Trigo JM, Bourhis J, Tortochaux J, Cortés-Funes H, Hitt R, Gascón P, Amellal N, Harstrick A, Eckardt A.

J Clin Oncol. 2005 Aug 20;23(24):5568-77. Epub 2005 Jul 11.


Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: a Gynecologic Oncology Group study.

Behbakht K, Sill MW, Darcy KM, Rubin SC, Mannel RS, Waggoner S, Schilder RJ, Cai KQ, Godwin AK, Alpaugh RK.

Gynecol Oncol. 2011 Oct;123(1):19-26. doi: 10.1016/j.ygyno.2011.06.022. Epub 2011 Jul 12.

Supplemental Content

Support Center